Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,227 recruiting studies in this area right now.
By phase
- Not applicable3,140
- Phase 21,067
- Phase 1822
- Phase 1/Phase 2446
- Phase 3423
- Phase 4236
- Phase 2/Phase 393
Top conditions
- Multiple Sclerosis342
- Multiple Myeloma333
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis142
- Type 1 Diabetes132
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia123
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Leukemia64
- Rheumatoid Arthritis (RA)64
- Acute Myeloid Leukemia62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- Novartis Pharmaceuticals65
- M.D. Anderson Cancer Center63
- AstraZeneca57
- City of Hope Medical Center46
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama176
- Florida143
- Arizona140
- New York122
- Massachusetts119
- Texas118
- Illinois82
- Colorado77
Recruiting studies6,227 total
- NCT07273708Recruiting
Immune cell study in liver cancer patients on immunotherapy
This study looks at how your immune cells respond to two specific immunotherapy-based treatments for advanced liver cancer. Researchers want to understand why some patients respond well and others do not, which could help improve future care.
Pavia, LombardyAges 18–90 - NCT07285889RecruitingPhase 1/Phase 2
Jaktinib as first treatment for acute graft-versus-host disease
This trial tests a new pill called jaktinib for people who develop moderate to severe acute graft-versus-host disease (aGVHD) after a stem cell transplant. The goal is to see if adding jaktinib to standard steroid therapy can better control the disease.
Hangzhou, ZhejiangAges 18 years+ - NCT06293053RecruitingPhase 3
Study of Dupilumab in children with prurigo nodularis
This trial tests a new medicine (Dupilumab) for children with a severe itchy skin condition called prurigo nodularis. It aims to see if the treatment is safe and how it works in the body.
Palo Alto, CaliforniaAges 6 months–17 years - NCT07374874Recruiting
Heart and nervous system health after stem cell transplant
This study looks at how your autonomic nervous system (the part that controls heartbeat and digestion) affects the risk of graft-versus-host disease (a condition where donor cells attack your body) after a half-matched stem cell transplant. You may be able to join if you are older than 16 and receiving a half-matched transplant from a family donor.
Tianjin, Tianjin MunicipalityAges 16 years+ - NCT07271381Recruiting
Testing how allergens and everyday toxins affect your body
This study looks at how common allergens and everyday toxins from things like cleaning products affect your skin, gut, and airways. It may help find ways to prevent or manage allergies and related health issues.
Bethesda, MarylandAges 18–80 - NCT07268872Enrolling by invitation
How anesthesia drugs affect immune function in healthy adults
This trial studies how different anesthesia drugs affect the immune system in healthy young adults. It may help doctors choose safer anesthetics for future patients.
Henan, ZhengzhouAges 20–30 - NCT05067595RecruitingPhase 1
Fecal transplant plus fiber for gut graft-versus-host disease
This Phase 1 study tests whether a fecal microbiota transplant (a stool-based treatment from a screened donor) plus a dietary fiber supplement can improve gut symptoms after a bone marrow transplant. It is aimed at people with mild to severe gut graft-versus-host disease (GVHD).
Seattle, WashingtonAges 18 years+ - NCT01244802Enrolling by invitation
Study of immune memory after yellow fever vaccination
This study looks at how your immune system “remembers” the yellow fever vaccine over time. It may help researchers understand long-term immune protection and how it varies between people.
Decatur, GeorgiaAges 18 years+ - NCT07338604RecruitingEarly Phase 1
UTAA07 cell therapy for relapsed CD7+ blood cancers
This trial tests a new cell therapy called UTAA07 for people with blood or lymph cancers that have returned or not responded to other treatments. It is designed for cancers that carry a specific marker called CD7, and aims to see if this therapy can help control the disease.
Suzhou, JiangsuAges 18 years+ - NCT07324733Recruiting
PSMA PET scan for Sjögren's syndrome
This study uses a special PET scan called PSMA to look at inflammation in Sjögren's syndrome, comparing the results with another type of PET scan (FAPI). It may help doctors better understand the disease and find new ways to track it.
BeijingAges 18–80 - NCT06823401Recruiting
Checking body response to lung cancer immunotherapy
This study looks at how your body reacts to checkpoint inhibitors (immunotherapy drugs like Keytruda or Opdivo) for NSCLC. It involves blood tests to check for antibodies your immune system might make against the drug.
Roma, RMAges 18 years+ - NCT06924762RecruitingPhase 2/Phase 3
Low-dose IL-2 for chronic hives that don't respond to usual treatment
This study tests a low-dose immune therapy (interleukin-2) for people with chronic hives that don't get better with standard allergy pills. If you are an adult with ongoing hives and itching despite daily antihistamines, this trial might offer a new treatment option.
Changsha, HunanAges 18–74 - NCT06783270RecruitingPhase 1
T-Cell Therapy for Advanced Melanoma
This trial tests a new T-cell therapy made from your own tumor (TILs), genetically edited to remove the PD1 checkpoint blocker. It may help your immune system fight melanoma that has not responded to standard treatments like anti-PD1 therapy.
Herlev, Capital RegionAges 18–75 - NCT07253259RecruitingEarly Phase 1
Cell therapy for hard-to-treat chronic graft-versus-host disease
This study tests a new cell therapy called GT729 for people with chronic graft-versus-host disease (cGVHD) that hasn't improved with at least two previous treatments. The therapy is given as an injection and aims to help control the immune system reaction that causes cGVHD.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT07251998RecruitingPhase 2
A study of ICP-332 for moderate to severe plaque psoriasis
This trial tests an oral medication called ICP-332 versus a placebo (a pill with no active drug) for people with moderate to severe plaque psoriasis. The goal is to see if ICP-332 can improve skin symptoms and be safe.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07248904Recruiting
HPV education study for first-year nursing students
This study tests whether a special education program based on the transtheoretical model improves nursing students' knowledge about HPV, their health beliefs, and their intentions to get vaccinated. It aims to help students make informed decisions about HPV prevention.
Adana, CUKUROVAAges 18 years+ - NCT07424222RecruitingPhase 1
Ruxolitinib for a serious immune reaction after CAR T therapy
This trial tests a drug called ruxolitinib for a rare but serious condition called IEC-HS that can happen after CAR T cell treatment. The goal is to see if ruxolitinib can calm this overactive immune response.
Baltimore, MarylandAges 18–99 - NCT06660329Enrolling by invitationPhase 4
Tofacitinib for hard-to-treat Blau syndrome
This study tests if the drug tofacitinib (a JAK inhibitor) can help people with Blau syndrome whose symptoms did not improve with other treatments. Blau syndrome is a rare genetic condition that causes inflammation in the skin, joints, eyes, and other organs.
BeijingAges birth–18 years - NCT07246460Recruiting
Ultrasound and protein tests to see if guselkumab works for Crohn's
This study tests whether guselkumab (a targeted drug) can effectively treat Crohn's disease in the ileum (last part of the small intestine). You will have ultrasound scans and blood tests to measure your response, which may help find the right dose and monitor for bowel healing.
Calgary, AlbertaAges Up to 80 years - NCT06923202Recruiting
Studying alloknesia in atopic dermatitis
This study looks at a condition called alloknesia (a feeling that a light touch is painful) in people with atopic dermatitis (a type of eczema). It aims to understand how common this is and what it feels like.
AngersAges 18 years+ - NCT06752057Recruiting
Personalized vaccine plus immunotherapy and radiation for advanced lung cancer
This study tests a combination of a personalized vaccine made from your tumor's unique markers, a type of immunotherapy (PD-1 inhibitor), and radiation. The goal is to see if this mix can work better for advanced lung cancer that has progressed after initial treatment.
Nanchang, JiangxiAges 18–70 - NCT06829238RecruitingPhase 4
Metformin to boost immune function in people with a history of drug use
This study tests whether metformin, a common diabetes drug, can help restore immune system balance in people who have used injection drugs in the past. It includes both people living with HIV and those who are HIV-negative.
Birmingham, AlabamaAges 18–64 - NCT06830798RecruitingPhase 3
Ravulizumab to prevent delayed graft function after kidney transplant
This study tests an investigational medicine (ravulizumab) given through a vein to see if it can prevent delayed graft function—meaning the new kidney takes longer to start working—after a high-risk kidney transplant. It is for adults on dialysis who are getting a kidney from a donor whose heart stopped or who is considered high-risk.
Phoenix, ArizonaAges 18 years+ - NCT06635863Enrolling by invitationPhase 4
Steroids versus standard heart medications for heart inflammation
This study compares two treatment strategies for people with unexplained heart failure and irregular heartbeats caused by inflammation: one group gets standard heart medications plus an immune-suppressing steroid (prednisone), and the other gets standard medications alone. Doctors want to see whether adding steroids helps improve heart function and control dangerous heart rhythms.
Phoenix, ArizonaAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,227 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,696 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.